Analysts expect Vaxcyte to post earnings of ($2.0556) per share and revenue of $12.50 million for the quarter. Amundi purchased a new stake in Vaxcyte in the 4th quarter valued at $235,000. Caxton Associates LLP acquired a new position in Vaxcyte in the 1st quarter valued at about $226,000. Cubist Systematic Strategies LLC purchased a new stake in Vaxcyte during the 1st quarter valued at approximately $219,000. Vaxcyte Company Profile(Get Free Report)Vaxcyte, Inc (NASDAQ: PCVX) is a clinical-stage biotechnology company focused on developing a new generation of preventive vaccines aimed at combating serious bacterial diseases.